ODAC meeting on checkpoint inhibitors could affect future of accelerated approval
Six indications for three drugs will be reviewed
Six indications for three drugs will be reviewed.
The integrity and future of FDA’s accelerated approval pathway will be on trial at next week’s Oncologic Drugs Advisory Committee meeting.
ODAC will be making recommendations about retaining or withdrawing six accelerated approvals for three PD-1